Abrdn logo

Abrdn

Europe, Edinburgh, City of, United Kingdom, Edinburgh

Description

Abrdn, headquartered in Edinburgh, United Kingdom, is a prominent global investment company primarily known for its asset management services. While not a traditional early-stage venture capital firm, Abrdn does engage in direct investments, particularly through its strategic investment team and private equity arm. These investments are typically focused on companies that align with Abrdn's core business, such as fintech, wealth management technology, and other financial services innovations. Their approach often involves participating in later-stage growth equity rounds rather than seed or Series A funding. This strategic focus differentiates their investment activities from typical venture capital funds.

For instance, Abrdn participated in a £35 million Series D funding round for the UK-based fintech Moneybox in 2021, demonstrating their commitment to supporting growth-stage companies in the financial sector. Another notable investment includes their participation in a £45 million Series C round for Nutmeg, a digital wealth manager, prior to Abrdn's full acquisition of the company. These examples highlight Abrdn's role in providing significant capital to established startups that have achieved considerable traction and are seeking further growth capital.

Abrdn's private equity activities also include investing in private equity funds and co-investing directly into companies alongside their fund managers. This dual approach means their capital deployment can range from indirect investments via funds to direct, strategic stakes in mature private companies. However, due to the nature of these strategic and growth equity investments, which are often part of larger syndicated rounds, reliable information on their typical 'first cheque' size for direct startup investments is not publicly disclosed or clearly defined in the manner of a dedicated venture capital fund.

Investor Profile

Abrdn has backed more than 21 startups, with 6 new investments in the last 12 months alone. The firm has led 4 rounds, about 19% of its total and boasts 4 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series A, Series B rounds (top funding stages).
  • Majority of deals are located in United States, United Kingdom, Canada.
  • Strong thematic focus on Biotechnology, Health Care, Life Science.
  • Led 1 rounds in the past year.

Stage Focus

  • Series C (19%)
  • Series A (19%)
  • Series B (19%)
  • Private Equity (14%)
  • Series Unknown (10%)
  • Post Ipo Equity (5%)
  • Post Ipo Debt (5%)
  • Debt Financing (5%)
  • Post Ipo Secondary (5%)

Country Focus

  • United States (48%)
  • United Kingdom (24%)
  • Canada (10%)
  • India (5%)
  • Argentina (5%)
  • Finland (5%)
  • Malaysia (5%)

Industry Focus

  • Biotechnology
  • Health Care
  • Life Science
  • Medical
  • Financial Services
  • Pharmaceutical
  • Therapeutics
  • Software
  • Oncology
  • Bitcoin
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Abrdn frequently co-invest with?

Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 2
Chase Capital Partners
North America, New York, United States, New York
Co-Investments: 2
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 2
RiverVest
North America, Missouri, United States, St Louis
Co-Investments: 3
Digitalis Ventures
North America, New York, United States, New York
Co-Investments: 2
Marshall Wace
Europe, England, United Kingdom, London
Co-Investments: 2
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 2
Sanofi Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2

What are some of recent deals done by Abrdn?

Glycomine

San Francisco, California, United States

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

BiotechnologyPharmaceuticalTherapeutics
Series CApr 16, 2025
Amount Raised: $115,000,000
Arbor Biotechnologies

Cambridge, Massachusetts, United States

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

BiopharmaBiotechnologyLife Science
Series CMar 18, 2025
Amount Raised: $73,900,000
Atalanta Therapeutics

Boston, Massachusetts, United States

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

BiotechnologyHealth CareLife Science
Series BJan 28, 2025
Amount Raised: $97,000,000
Aviceda Therapeutics

Cambridge, Massachusetts, United States

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series CJan 7, 2025
Amount Raised: $207,500,000
Alpha9 Theranostics

Vancouver, British Columbia, Canada

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

BiotechnologyMedicalProduct Research
Series COct 23, 2024
Amount Raised: $175,000,000
Radiant Biotherapeutics

Toronto, Ontario, Canada

Radiant is a biotechnology company developing the next generation of multi-specificity.

BiotechnologyTherapeutics
Series ASep 11, 2024
Amount Raised: $35,000,000
Third Arc Bio

Boston, Massachusetts, United States

Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.

BiotechnologyHealth CareLife ScienceMedicalOncology
Series AJul 23, 2024
Amount Raised: $165,000,000
Qlaris Bio

Wellesley, Massachusetts, United States

Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.

BiotechnologyHealth CareMedical
Series BApr 30, 2024
Amount Raised: $24,000,000
Sammaan Capital

Mumbai, Maharashtra, India

Sammaan Capital offers home loans in the affordable housing segment.

CreditFinancial ServicesLendingReal Estate
Post Ipo DebtMar 27, 2024
Amount Raised: $347,887,202
Engrail Therapeutics

San Diego, California, United States

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Health CareLife ScienceMedicalPharmaceutical
Series BMar 19, 2024
Amount Raised: $157,000,000